Computational and experimental druggability assessment of human DNA glycosylases by Michel, M. et al.
This is a repository copy of Computational and experimental druggability assessment of 
human DNA glycosylases.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/154433/
Version: Published Version
Article:
Michel, M., Visnes, T., Homan, E.J. et al. (12 more authors) (2019) Computational and 
experimental druggability assessment of human DNA glycosylases. ACS Omega, 4 (7). pp.
11642-11656. ISSN 2470-1343 
https://doi.org/10.1021/acsomega.9b00162
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless 
indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by 
national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of 
the full text version. This is indicated by the licence information on the White Rose Research Online record 
for the item. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Computational and Experimental Druggability Assessment of
Human DNA Glycosylases
Maurice Michel,*,,∇ Torkild Visnes,,,∇ Evert J. Homan, Brinton Seashore-Ludlow,§
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ABSTRACT: Due to a polar or even charged binding interface, DNA-binding
proteins are considered extraordinarily difficult targets for development of small-
molecule ligands and only a handful of proteins have been targeted successfully to
date. Recently, however, it has been shown that development of selective and
efficient inhibitors of 8-oxoguanine DNA glycosylase is possible. Here, we describe
the initial druggability assessment of DNA glycosylases in a computational setting
and experimentally investigate several methods to target endonuclease VIII-like 1
(NEIL1) with small-molecule inhibitors. We find that DNA glycosylases exhibit
good predicted druggability in both DNA-bound and -unbound states.
Furthermore, we find catalytic sites to be highly flexible, allowing for a range of
interactions and binding partners. One flexible catalytic site was rationalized for
NEIL1 and further investigated experimentally using both a biochemical assay in
the presence of DNA and a thermal shift assay in the absence of DNA.
■ INTRODUCTION
The concept of inflicting damage to DNA in tumor cells to treat
cancer, e.g., by radiation therapy or chemotherapeutics such as
antimetabolites and DNA intercalators, has formed the
foundation of modern clinical oncology.1,2 The success of
these first-line cancer treatments have prompted increased
attention toward enzymes that repair damaged bases and to the
development of corresponding small-molecule inhibitors for
cancer therapy. We and others have shown that Mut T homolog
1 (MTH1) inhibition leads to incorporation of oxidized bases
such as 7,8-dihydro-8-oxoguanine (8-oxoG) into DNA and
selectively kills cancer cells.3−7 Despite the unclear underlying
biology of MTH1 inhibition,8 it is evident that cancer cells
depend on protective repair pathways to tolerate increased
oxidative stress. Therefore, we argue that further inhibition of
the main DNA repair pathways for repair of oxidized
nucleobases, in particular the base excision repair proteins 8-
oxoguanine DNA glycosylase (OGG1), Mut Y homolog
(MUTYH), or NEIL1, could lead to powerful combination
therapies.9−15 OGG1, the DNA glycosylase responsible for
repairing the bulk of 8-oxoG in mammals,16,17 has recently been
validated preclinically as a drug target by us and others, proving
druggable with selective small molecules.18,19The importance of
managing 8-oxoG levels is also facilitated by MUTYH, which
removes adenine misincorporated opposite to 8-oxoG.20 This
initiates recycling of the damaged DNA strand back to OGG1,
which otherwise fails to recognize 8-oxoG unless it is base-paired
with cytosine. NEIL1, on the other hand, has a unique substrate
range, removing all products formed from further oxidation and
fragmentation of 8-oxoG, but also thymine glycol (Tg), oxidized
cytosine and uracil.12,21−24 Mice devoid of these DNA
glycosylases are viable and grow old, suggesting that potential
inhibitors would show little on-target toxicity in a rodent
model.25,26
DNA glycosylases exist in DNA-bound and -unbound
conformations.19,27−32 It is of interest whether a DNA-bound
or -unbound state facilitates or restricts the binding of small
molecules. Thus, one major challenge is to be able to target one
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population of a DNA glycosylase with a small molecule, given
that this is a requirement for conveying a certain phenotype.19
Computational binding-site prediction, for example, is a suitable
method to investigate chemotype preference of DNA
glycosylases using available crystal structures of single isolated
protein species. However, literature concerning druggability of
any DNA glycosylase is nonexistent and reported findings are
only applicable in the broadest sense by transferring knowledge
from glycosylases and RNA-, DNA-, nucleotide-, and carbohy-
drate-binding proteins.3,33−36 Additionally, these previous
studies based on crystal structures have considered the relevant
proteins to be rigid and not flexible, a scenario that is not
applicable to DNA glycosylases.
Druggability is defined as the ability of a protein to specifically
bind rule-of-five-compliant small molecules with high affin-
ity.37−39 A high druggability score and the induction of a
therapeutic effect by small-molecule binding in a living system
are characteristics of a good drug target. Several computational
and empirical methods to assess protein druggability have been
reported over the past years.40−42 Computational druggability
predictions are less time-consuming and relatively cheap
compared to experimental methods. Given the availability of
structural information, i.e., high-resolution crystallographic data,
they allow for the rapid evaluation of target suitability for a drug
discovery campaign. A number of computational methods
predicting protein-binding sites and their druggability are
available,33,43−46 spanning the entire spectrum from geometric
to energy-based and from rigid proteins to systems allowing for
high flexibility.
High-throughput screening (HTS) of large druglike com-
pound libraries has yielded a number of hits for NEIL1 and
OGG1 with micromolar (μM) potency.18,47,48 However, target
screening using rule-of-three-compliant fragment libraries may
be more productive, since it can assess the target’s druggability.
Furthermore, fragment screening also covers a larger chemical
space and typically yields hits with higher ligand efficiencies,
which are often more amenable for further lead generation than
μM druglike hits.35,49−51 Techniques commonly used for
fragment screening are biophysical methods such as surface
plasmon resonance (SPR), nuclear magnetic resonance (NMR),
differential scanning fluorimetry (DSF), and X-ray crystallog-
raphy.52
Here, we performed a computational binding-site prediction
and druggability assessment of available high-resolution
structures of human DNA glycosylases using different
algorithms and experimentally assessed the computationally
derived druggability scores for NEIL1. We show structures
identified in the biochemical HTS, assess their target engage-
ment in DSF, and importantly, suggest a broadly applicable
adaptation of DSF for DNA-binding proteins.
■ RESULTS AND DISCUSSION
Sequence Alignment Reveals Low Sequence Con-
servation of DNA Glycosylases. Initially, we compiled a list
of all available high-resolution crystal structures of human DNA
glycosylases (Table 1) and assessed consensus protein sequence
by alignment of FASTA at Clustal Omega at EMBL.3,27−30,53−64
Sequence similarity was extraordinary low, with an average of
15.5% (Figure 1B).65 This is in accordance with earlier reports
that assort the low sequence similarity of especially the uracil-
binding glycosylases to the major role of uracil flipping.66 This
seems to be due to a conformational strain caused by the enzyme
on uracil-containing DNA, which is much bigger compared to
the catalytic action of individual polar residues. Thus, it was
observed that despite their low sequence similarity, bacterial
uracil−DNA glycosylase and mismatch-specific uracil−DNA
glycosylase exhibit an almost identical global folding. Even so,
two different groups can be distinguished by the phylogenetic
tree (Figure 1A,B): NEIL1, NEIL2, and NEIL3 with a similarity
between 19.6 and 26.1%, and MPG, UNG, SMUG1, MUTYH,
NTH1, and OGG1 with a similarity between 11.9 and 24.1%.
Furthermore, the root-mean-square deviation (RMSD) of
atomic (Cα) positions for the pairs available for NEIL1 (0.84
Å), UNG (1.05 Å), MBD4 (0.88 Å), and OGG1 (0.85 Å) are
small and suggest that possible protein flexibility is either caused
by conformational changes of the amino acid side chains or by
existence of only a few higher-valued amino acids.
Computational Binding-Site Analysis by DogSite
Predicts Good Druggability. We then predicted binding
pockets and assessed druggability of the high-resolution crystal
structures. Generally, hydrophilic sites are considered less
druggable than more hydrophobic sites. This effect should in
theory yield low scores for DNA-binding regions of the proteins.
We identified between 1 and 11 potential binding sites for each
DNA glycosylase. Except for DNA-bound MBD4 (4OFA),57 at
least two sites were found to be druggable by the definition of
DogSite (drug score > 0.5). For all structures except apo MBD4
(4E9E),56 DNA-bound NEIL1 (5ITY),29 apo OGG1
(5AN4),27 and DNA-bound TDG (5HF7),60 the active site
with catalytic amino acid residues was identified as the top-
ranking binding pocket. Apo NEIL1 (1TDH)30 was the only
structure where two distinct binding pockets were identified
close to amino acid residues involved in the catalytically active
site. Finally, closely situated binding sites in apo, DNA-bound,
and DNA-stripped structures scored differently and, in addition,
were found to have different size and altered amino acid
composition.
Table 1. List of Analyzed Crystal Structures of Human DNA
Glycosylasesa
protein
name
PDB
code w/DNA w/o DNA apo reference
MBD4 4E9E X Moreŕa et al.56
MBD4 4OFA X Ouzon-Shubeita et
al.57
MBD4 4OFA X Ouzon-Shubeita et
al.57
MPG 1EWN X Lau et al.64
MPG 1EWN X Lau et al.64
MUTYH 3N5N X Luncsford et al.62
NEIL1 1TDH X Doublie ́ et al.30
NEIL1 5ITY X Zhu et al.29
NEIL1 5ITY X Zhu et al.29
NEIL3 3W0F X Liu et al.61
OGG1 5AN4 X Zander et al.27
OGG1 2XHI X Dalhus et al.28
OGG1 2XHI X Dalhus et al.28
TDG 5HF7 X Coey et al.60
TDG 5HF7 X Coey et al.60
UNG 2HXM X* Krosky et al.59
UNG 1EMH X Parikh et al.58
UNG 1EMH X Parikh et al.58
MTH1 3Q93 X Tresauges et al.69
PTP1B 2HNP X Barford et al.76
aMTH1 and PTP1B were included as reference proteins; * ligand
removed.
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Although therapeutically targeting DNA glycosylases with
small molecules requires inhibition of DNA−protein complex
formation, this may be achieved without direct ligand binding to
the active site. Despite possible involvement in protein
regulation or allosteric sites, inhibition of remote sites is not
generally considered a requisite for eliciting a therapeutic
effect.67We therefore assigned the predicted binding sites to one
of four categories: Active site with catalytic amino acid residue I,
active-site adjacent pocket II, DNA-binding groove III, and
remote binding sites IV (Figure 2A). For each protein, the
single, top-ranking pocket for the categories I, II, and III was
used to calculate a mean druggability score. With a druggability
score of 0.80, DNA glycosylases were identified as favorably
druggable. The druggable reference protein MTH1
(3Q93)3,7,68,69 was found to score slightly higher with 0.81.
The protein tyrosine phosphatase 1B (PTP1B)was included as a
negative control. PTP1B is widely accepted as a potential
therapeutic target for type 2 diabetes and obesity,70−72 and for
this reason, numerous potent and structurally diverse PTP1B
inhibitors have been discovered over the last two decades.73−75
Most of the inhibitors incorporate phosphotyrosine (pTyr)
mimetics and bind to the enzyme’s catalytic site. However, the
highly conserved and polar nature of the PTP1B catalytic site in
combination with a catalytically active cysteine renders
development of PTP1B inhibitors with good selectivity and
permeability a challenging task. So far, only three small-molecule
PTP1B inhibitors, including allosteric drugs, have progressed
into clinical trials.75 The catalytic site of PTP1B (2HNP)76
scored 0.72 by combination of two small sites, which separately
scored 0.41 and 0.56. Interestingly, OGG1 (2XHI),28 TDG
(5HF7),60 and UNG (1EMH)58 show especially high drug
scores of >0.85 for the catalytic site, while 0.66 for apo MBD4
(4E9E)56 was the only one indicating a challenging drug
discovery campaign (Figure 2B). In contrast to DNA-, RNA-,
Figure 1. Phylogenetic tree (A) and sequence alignment (B) of human DNA glycosylases. Despite recognizing damaged DNA by flipping out the
corresponding base, human DNA glycosylases have a surprisingly low sequence similarity even among those classified in the same protein family such
as the endonuclease VIII-like members.
Figure 2. (A) DogSite was used to predict binding sites in available high-resolution crystal structures of human DNA glycosylases. Each predicted
binding site was further assessed for its DrugScore, i.e., computational derived druggability score. Values between 0.5 and 1.0 define a pocket as
druggable, of which values closer to 1.0 are considered the best. Identified binding sites of DNA glycosylases can be sorted into four categories: I
catalytic site (green); II catalytic adjacent site (yellow); III part of DNA groove (orange); IV other remote sites (black). Except for apo MBD4, DNA-
bound NEIL1, apo OGG1, and DNA-bound TDG, the algorithm identified the catalytic sites as the highest ranking pocket. Surprisingly, most high
scoring sites reached a DrugScore as high as the binding site of MTH1, a well-characterized and druggable protein. (B) To induce a therapeutic effect,
perturbation of DNA binding is a sufficient mode of action for a prospective small-molecule drug. Therefore, for each protein, only the single highest
ranking DrugScore of category I, II, or III was used to calculate a mean druggability score for human DNA glycosylase. With an average DrugScore of
0.80, DNA glycosylases identify as favorably druggable targets (MTH1 0.81, PTP1B 0.72).
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and carbohydrate-binding proteins and based on remarkably
high DogSite generated druggability scores, this indicates that
DNA glycosylases are indeed druggable.33−36
Binding-Site Assessment with SiteMap Identifies
Dependency of Pocket Polarity on the Presence of
DNA. Schrödingers SiteMap is commonly used to assess protein
surfaces for binding pockets and their druggability, i.e., Dscore.
The Dscore favors proteins with more hydrophobic binding
pockets, and proteins reaching Dscores higher than 1.108 are
considered excellent drug targets, while proteins with values up
to 0.871 are considered difficult.77,78 For comparison, the largest
identified site for the undruggable PTP1B (2HNP)76 showed a
Dscore of 0.77, while MTH1 (3Q93)69 scored 1.02. Between
one and eight sites were found for DNA glycosylases by
SiteMap, with Dscores ranging from nondruggable to druggable
(Figure 3A). The single highest scoring sites of categories I, II,
and III reached amean Dscore of 0.89, scoring below the Dscore
of MTH1 (3Q93)69 of 1.02, but clearly above PTP1B
(2HNP).76 The range of Dscores between 0.59 and 1.11 on
the other hand reflects a rather distributed picture of the
different target proteins. Although slightly lower than in
DogSite, these results confirm the finding of good druggability
of human DNA glycosylases.
One important characteristic of a druggable binding pocket is
a favorable hydrophobic/hydrophilic balance. This is the main
point of concern regarding druggability of DNA-binding
proteins, since high-affinity DNA binding requires a network
of polar amino acid residues. Thus, it was of interest to
determine whether the polarity of the highest ranking sites
allows for the binding of druglike molecules, which are usually
more hydrophobic than DNA. When investigated for these
parameters using the incorporated function in SiteMap, the
single highest scoring sites of human DNA glycosylases score on
average 0.49, respectively, 0.69 for MTH1 (3Q93)69 and 0.05
for PTP1B (2HNP),76 with a range of 0.07−2.90 (Figure 3B).
Apo structures tend to be higher ranking, as only UNG with
bound DNA (1EMH)58 reaches hydrophobicity levels higher
than MTH1 (3Q93).69 As an extreme example, apo NEIL1
(1TDH)30 scored a hydrophobic/hydrophilic ratio of 2.90. In
contrast, the corresponding DNA-bound proteins score
substantially lower (0.16−0.38), suggesting major conforma-
tional changes upon DNA binding. In total, only MUTYH
(3N5N),62 NEIL1 (1TDH),30 NEIL1 w/DNA (5ITY),29
OGG1 (5AN4),27 TDG w/DNA (5HF7),60 and UNG w/
DNA (1EMH)58 are feasible drug targets judging by a pocket
polarity over 0.5 (Figure 3B).
In Silico Docking of ZINC Fragments to Human DNA
Glycosylases. As an additional method to investigate the
obtained druggability scores and pocket polarities, we
performed virtual screens of a subset of the open-access ZINC
database against the highest scoring binding site of each DNA
glycosylase, as identified by SiteMap.79,80 An obvious advantage
of this screening campaign is that top-ranked fragments could
provide potential starting points for hit expansion and lead
Figure 3. (A) As a second algorithm, SiteMap of Maestro from Schrödinger was used to predict binding sites and calculate the corresponding Dscores.
Values below 0.871 reflect a challenging nature of the target, while proteins reaching values larger than 1.108 are considered excellent drug targets.With
the highest ranking pocket of category I, II, or III, DNA glycosylases yield an average DScore of 0.89 (MTH1 1.020, PTP1B 0.770) and are predicted to
be druggable targets. (B) Polarity of active sites are a main concern when targeting DNA-binding proteins. Indeed, DNA glycosylases bound to DNA
tend to exhibit higher hydrophilicity than apo structures. These values, however, do not reflect a general trend that excludes druggability of DNA
glycosylases judging by pocket polarity. (C) Venn diagram illustrating that all proteins considered druggable by SiteMap are also considered druggable
by DogSite. A large percentage of these show sufficient polarity or hydrophobic/hydrophilic ratio to be targeted by classic rule-of-five-compliant small
molecules. (D) Docking scores generated during in silico screening of a subset of the ZINC library to the highest ranking site are an additional measure
to estimate the druggability of a target. Here, the top-1000 ranked fragments against every DNA glycosylase cover a broad spectrum with docking
scores as low as those reached against MTH1 and higher scores for the hydrophobic site of apo NEIL1 and beyond PTP1B.
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generation. We hypothesized that the docking score profiles of
the top-ranked 1000 fragments would reflect the druggability of
the respective sites, i.e., protein pockets with good druggability
scores should yield lower average fragments scores. By applying
a cascade of docking steps with increasing scoring precision, the
top-ranked 1000 fragments against each DNA glycosylase were
retained and the median Glide XP docking scores for each of the
top-ranked 1000 fragment sets were calculated. Figure 3C
summarizes the docking score profiles and shows the scores of
the 1000 top-ranked fragments against human DNA glyco-
sylases. The fragment docking profile of MTH1 (3Q93)69
clearly stands out with the top-1000 fragments scoring between
−10.7 and −15.7 kcal/mol, and median docking score of −11.4
kcal/mol, supporting the in silico druggability assessments and
experimental data of MTH1 being highly druggable. In support
of this are results obtained from our in-house fragment screen
against purified MTH1 using DSF, which yielded a hit rate of
10% (unpublished results) and the high DSF fragment screen hit
rate of 23% obtained by Rahm et al.81 Furthermore, the
enzymatic HTS resulting in the TH588 series of MTH1
inhibitors showed a hit rate of 4%.3 In contrast, PTB1B
(2HNP),76 known to be a challenging target for small-molecule
intervention at the catalytic site, displayed a median docking
score of −6.7 kcal/mol, with scores for the top-1000 fragments
ranging from −6.2 to −8.5 kcal/mol. For the DNA glycosylases,
median fragment docking scores are found between −4.8 and
−9.0 kcal/mol, and with an average median docking score of
−7.1 kcal/mol. Importantly, a clear difference in docking score
profiles for apo and DNA-bound structures of the same protein,
e.g., NEIL1, MBD4, OGG1, and UNG, can be observed. This
effect canmostly be attributed to the slightly different location of
the binding sites identified by SiteMap and used for docking in
this experiment. Interestingly, DNA-bound structures of DNA
glycosylases tend to perform better than apo structures, as the
five poorest scoring proteins are apo structures. Apo NEIL1
(1TDH)30 showed a poor docking score profile with a median
docking score of−5.3 kcal/mol. This stands in sharp contrast to
the earlier observation of its high druggability scores obtained in
all algorithms. The high Dscore (1.11) of the largest pocket,
adjacent to the catalytic site in the DNA-bound structure, is
primarily caused by the highly favorable hydrophobic/hydro-
philic balance of 2.90. The ZINC fragment subset, however, was
tailored toward fragments with good H-bond formation
possibilities. This may explain the suboptimal complementarity
of a large proportion of fragments with this hydrophobic site.
Arg242 Flexibility Alters NEIL1 Binding-Site Polarity.
In an attempt to structurally rationalize the findings from above
for NEIL1, we inspected both the highest ranking binding sites
in apo (1TDH)30 and DNA-bound (5ITY)29 forms. A major
difference can be observed in close proximity, as inward
movement of a flexible loop brings the terminal guanidine group
of Arg242 in position to coordinate the tautomerized lactim
moiety of the former lactam thymine glycol substrate in the
DNA-bound structure, allowing for energetically favored
stabilization (Figure 4).29 This conformation is absent in the
apo structure where Arg242 points outward, rendering this
particular region a hydrophobic site. This observation is further
supported by the presence of three glycine residues in the direct
vicinity of Arg242 (motif GGRGY), as glycine in higher
numbers are known to enhance flexibility of protein active
sites.82,83 Taken together, the microenvironment of Arg242
suggests possible application in inhibitor design, where
prevention of Arg242 inward movement allows for the required
hydrophobicity to target NEIL1 with small molecules.
Considering this importance of Arg242 and the large substrate
specificity of NEIL1, we decided to perform a binding site
prediction allowing for amino acid flexibility in DNA
glycosylases.
Catalytic Sites Are Conformationally Flexible. The
process of predicting binding sites and their druggability with
DogSite and SiteMap is solely based on the proteins’ crystal
structure and thus cannot compensate for the conformational
flexibility, which DNA glycosylases in general and NEIL1 in
particular seem to require upon DNA binding. CryptoSite is a
web-based server, which can detect holo sites in apo structures of
proteins by interrogating flexibility of single amino acid
residues.44 A cryptic value above 0.10 identifies a position of a
potential cryptic network, i.e., cryptic site. The structures of
human DNA glycosylases yield an average of 0.30 with values
from 0.12 to 0.46 for their respective catalytically active sites
(Figure 5A, left). Furthermore, an extended network of amino
acids around these pockets shows the same tendency of elevated
cryptic values (Figure 5A, right). On average, 39 residues are
involved in an anticipated movement, ranging from 15 for MPG
devoid of DNA (1EWN)64 to 69 residues for MUTYH
(3N5N).62 This confirms the good observed druggability of
the space surrounding the catalytic sites in DNA glycosylases
from above and indicates a concerted movement of a three-
dimensional amino acid network during DNA binding. These
findings, taken together with the results obtained with DogSite
and SiteMap indicate a rather good druggability of human DNA
glycosylases and, in addition, suggest DNA binding to occur in
conformationally active sites (Figure 5B). Based on our DogSite
and SiteMap results, these often highest scoring pockets may
therefore be targeted with small molecules that initiate a number
of conformational changes.84,85 Earlier investigations of bacterial
formamidopyrimidine DNA glycosylase (Fpg) suggest that syn-
and anti-orientation of 8-oxo-guanine nucleobase and furanose
are not discriminated during base recognition in a living system.
This observation and our recent investigation of inhibitor
binding to mOGG1 (6G3Y)19 confirm the obtained inducible
flexibility in the present study and stand in sharp contrast to
earlier reports based on rigid protein conformation.19,33−36 The
contrast in druggability scores provided by the pair apo NEIL1
Figure 4. Superimposed structures of apo NEIL1 (turquoise, 1THD)
and DNA-bound NEIL1 (purple, 5ITY) close to the catalytic pocket
show little conformational flexibility of the peptide backbone (RMSD
0.84 Å). However, during DNA-binding events, the hydrophobic patch
(yellow) in the apo state is occupied by the flexible (motif GGRGY)
and polar guanidine side chain of Arg242. This inward directed
movement enables coordination of the lactim group of thymine glycol
and highlights DNA binding by NEIL1 as a process under allosteric
control in a conformationally active pocket.
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(1TDH)30 and DNA-bound NEIL1 (5ITY)29 most likely
reflects the broad substrate specificity of NEIL1 and possible
syn- and anti-orientation of each substrate.86,87 Considering
DogSite, SiteMap, and polarity, NEIL1 is among the most
promising proteins in the family of DNA glycosylases (Figure 3).
For these reasons, we decided to investigate NEIL1 for its
experimental druggability using several experimental screening
methods.
NEIL1 Activity Assay Development and HTS.NEIL1 is a
bifunctional DNA glycosylase with comparatively broad
substrate specificity, excising oxidized pyrimidines followed by
an associated β- and δ-lyase activity acting on the apurinic (AP)
site.22 Thus, to develop a biochemical activity assay, a duplex
oligonucleotide containing an internally quenched fluorophore
was used. A NEIL1 substrate nucleobase in the form of thymine
glycol (Tg) was positioned six base pairs from the 5-terminal
Figure 5. (A) Druggability assessment by CryptoSite allows for interrogation of single amino acid flexibility that in the form of larger clusters in close
proximity causes formation of allosteric sites. Each amino acid is considered to be a cryptic site when reaching CryptoSite values above 0.10. Most
identified cryptic sites in humanDNA glycosylases are positioned close to the catalytic site (values in green) or pocket and form a comprehensive three-
dimensional network with one another (number of amino acids participating in black), supporting the hypothesis of allosteric sites controlling DNA
binding. (B) Illustration of identified highest ranking cryptic sites in apo NEIL1 (1THD; increasing CryptoSite value from blue to red) confirms the
sites to be part of the catalytically active pocket.
Figure 6. (A) Fluorigenic biochemical assay. An oligonucleotide (10 nM) containing thymine glycol or canonical thymine opposite adenine (Tg/A
and T/A, respectively) was incubated with the indicated concentations of NEIL1, or 0.5 units of the E.coli ortholog endonuclease VIII (EndoVIII).
Enzymatic treatment caused a concentration-dependent increase in fluorescence for Tg/A, but not T/A substrate. (B) High-throughput screen for
NEIL1 inhibitors; 20 nM Tg/A substrate was incubated with 10 nM NEIL1, in the presence of 10 μM test compounds (light blue circles), 0.1%
dimethyl sulfoxide (DMSO) (white circles), or 100 μM positive control inhibitor CGP-74514A48 (red circles). A total of 64 compounds inhibited
NEIL1 > 36%; 49 compounds are excluded from the diagram due to excessive autofluorescence (<−200% apparent NEIL1 inhibition). (C) Selected
chemotypes found in the high-throughput screen. (D) Representative IC50 curves of control compound CGP-74514A and confirmed hits.
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fluorophore. Excision of thymidine glycol, followed by incision
at the AP site by the associated lyase activity of NEIL1 led to a
localized melting of the DNA helix, causing the fluorophore to
be released from the quencher.88 Both NEIL1 and E. coli
endonuclease VIII (Nei) enzymes were able to cause release of
fluorescence from the oligo duplex containing Tg. No such
increase was observed for the control oligonucleotide containing
a normal thymine instead of thymine glycol. Importantly, a
NEIL1 concentration-dependent increase in signal with a signal-
to-noise ratio at around ∼20 was observed (Figure 6A). The
assay was used to perform a high-throughput screen, as an
orthogonal method for small-molecule hit confirmation and for
determination of IC50 values.
A total of 30 114 compounds were screened to identify
potential inhibitors. As positive control for inhibition, the
previously identified NEIL1 inhibitor analogue CGP-74514A
was employed at 100 μM concentration.48 Using this setup, an
average Z factor of 0.69 (n = 86 plates) was achieved, indicating
that the assay was sufficiently robust to identify inhibitors.
Indeed, 64 compounds (an initial hit rate of 0.21%) were found
to inhibit the enzymatic reaction by 36% or more (Figure 6B);
12 of these were excluded from further analysis due to structural
frequent hitter behavior and pan-assay interference alerts. The
remaining 52 compounds were then tested in three-dose
confirmation assays and counterscreened for DNA intercalation.
Here, 14 compounds failed to produce a dose-dependent
inhibition and 17 compounds were found to intercalate DNA to
some extent. The remaining 21 compounds were subjected to
dose−response assays, where the chemotypes of TH8187 and
TH6319, as well as adenine analogues of CGP-74514A were
confirmed to be low μM inhibitors of NEIL1 (Figure 6C).48,89
DSF Fails to Validate Target Engagement of Bio-
chemical Activity Screen Hits. Differential scanning
fluorimetry90,91 is a fast and readily available method to
experimentally assess protein druggability and target engage-
ment in vitro. In addition, the advantages of fragment-based
drug design render DSF the ideal tool to add complementary
chemical starting points to a medicinal chemistry campaign.
Initially, the hits from HTS and their analogues were used to
perform validation of target engagement. The melting temper-
ature Tm of NEIL1 was found to be below physiological
temperatures. Furthermore, earlier reported ligands for NEIL148
and chemotypes obtained in the screen above failed to
significantly stabilize NEIL1Δ56 (Figure 7A). Only TH8187
and TH6319 and analogues thereof were able to stabilize about
1.3 °C at 200 μM in a 96-well plate setup.
DNA-Binding Proteins Are Thermally Stabilized by
DNA. NEIL1 interacts with DNA in a mechanism where a
nucleobase is “flipped out” and continuously interrogates the
respective DNA strand for damaged nucleobases.92 This process
should stabilize NEIL1 through the formation of several
interaction patterns. Possible phosphate−amino group salt
bridges and multiple hydrogen bonds are readily observed
when inspecting the respective thymine glycol-bound crystal
structure (5ITY). Indeed, when added to the DSF assay, DNA
stabilized NEIL1 to higher melting temperatures (Figure 7B).
Furthermore, this effect was enhanced, when thymine glycol or a
THF analogue of an abasic site was incorporated into DNA
oligonucleotides (Figure 7C).We then investigated whether this
effect was applicable to other DNA-binding proteins. OGG1,
APE1, NEIL2, and TDG were stabilized in a length-dependent
manner by DNA. Additionally, OGG1 showed increased Tm in
the presence of 8-OxoG and the abasic-site analogue, while
NEIL2 and APE1 were stabilized by the abasic-site analogue
(Figure 7C−F).
Figure 7. In vitro target engagement confirmation using differential scanning fluorimetry. (A) Hits from the HTS were incubated with NEIL1Δ56 at
200 μM concentration in the absence of DNA, and thermal stabilization was assessed. However, NEIL1Δ56 was only marginally stabilized by hit
compounds. (B) Thermal stabilization of NEIL1 Δ56 by undamaged double-stranded DNA is dose-dependent and peaks above physiological
temperature at >40 °C. (C) The same effect is observed for longer DNA oligos (50 bp, 100 bp) and for damaged DNA modifications known to be
recognized by NEIL1 (Tg, AP). (D−G) NEIL2, OGG1, APE1, and TDG are thermally stabilized by DNA in the same substrate- and/or length-
dependent manner. (H)DNA does not stabilize NEIL1Δ56 in the presence of hit compounds. An adapted version of the target engagement assay with
DNA being added after incubating NEIL1Δ56 with the HTS hits confirms target engagement.
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Modified DNA−DSF Assay Validates Target Engage-
ment by NEIL1 HTS Hits. Based on the observation from
above, a compound that inhibits thymine glycol excision in a
biochemical activity assay should also result in a different Tm for
NEIL1 in the presence of DNA. Consequently, the HTS hits
were incubated with NEIL1 and, in a second step, DNA was
added. The HTS hits induced a Tm shift between 5.0 and 7.1 K
and on average 6.1 K relative to the Tm of 40.0 °C measured for
the NEIL1Δ56-DNA control (Figure 7H). These results
indicate a reduced formation of a DNA−protein complex in
the presence of inhibitor and confirm target engagement in a
category I, II, or III pocket. In summary, we suggest DSF in the
presence of DNA as an additional alternative method for
assessment of in vitro target engagement of DNA-binding
proteins.
DSF Fragment Screen against NEIL1 and OGG1. In
contrast to the biochemical activity screen, a fragment screen in
the absence of DNA relies on an unbiased protein−binder
interaction and should in principle pick up hits that bind all
available binding sites on the protein. In fragment screens,
observed hit rates are usually much higher compared to
conventional HTS and typically lie between 3 and 10%. We
performed a DSF-based fragment screen of NEIL1 in the
absence of DNA using a library that consists of 1000 fragments
covering diverse chemical space (Figure 8), and 200 hand-
picked nucleobase-like fragments. In this particular screen, we
defined a hit as stabilizing more than the positive control
TH8187 or 3 times the standard deviation of all DMSO controls.
Using these definitions, a screen of the 1200 fragment library
(average Tm 36.4 °C with a standard deviation of 0.94 °C) gave
an initial hit rate of 4.3%, or 52 fragments. After revalidation in
DSF, purity confirmation by liquid chromatography-mass
spectrometry, and, if required, identity confirmation by NMR,
a final set of 25 confirmed hits remained, corresponding to a hit
rate of 2.1%. Next, validation of these fragments was performed
in the orthogonal biochemical activity assay using a concen-
tration series; 10 compounds or 40% of identified fragment hits
showed inhibition of NEIL1-mediated Tg repair in the low μM
range and thus confirmed interaction with pocket categories I, II,
or III.
This hit rate is at the lower end of commonly observed
fragment screening hit rates and stands in contrast to the
computational assessment of NEIL1. To investigate whether
this observation is reproduced for other DNA glycosylases, we
expanded our fragment screening campaign to OGG1. We and
others have recently shown that OGG1 can be specifically
inhibited by druglike small molecules.18,19 Tm of OGG1 in DSF
was 43.2 °C, a hit was considered to stabilize at least 1 °C, and
TH548719 was used as a positive control. The corresponding
fragment screen (average Tm of 43.1 °C and a standard deviation
of 0.82 °C) initially yielded 62 fragment hits or a hit rate of 5.2%.
After revalidation in DSF, and purity and identity confirmation,
35 molecules or 2.9% of the initial library remained. These
compounds, occupying different chemical space as previously
published OGG1 inhibitors,18,19 were then tested in the
biochemical OGG1 activity assay, where 16 fragments (46%)
showed inhibition of 8-oxoG excision. Despite the slightly
higher hit rate compared to NEIL1, these results indicate that
DNA glycosylases show lower hit rates than expected by
computational assessment.
NEIL1 NMR Fragment Screen. Fragment screens per-
formed in different assays, such as DSF, SPR, and saturation
transfer difference (STD)-NMR, may yield a different number
of binder and not necessarily confirm small-molecule binding of
a different method. To assess whether the experimental
druggability scores identified for NEIL1 and OGG1 in DSF
could be confirmed by a different biophysical screening method,
an STD-NMR screen was performed against NEIL1 in the
absence of DNA. In STD-NMR, small-molecule binders to the
surface of the target protein are identified after differencing the
pure protein NMR spectra from a spectrum with small
molecules added to the same protein. Due to little spectral
overlapping of small molecules, typical samples contain between
5 and 10 individual compounds. This approach allows for the
rapid screen of larger-fragment libraries. In the present case,
using an 800-member subset of the commercially available
Figure 8. Comparison of the 200 K member virtual fragment library selected from ZINC Fragments Now (ZFN, gray), the laboratory for chemical
biology at Karolinska Institutet (LCBKI) DSF fragment library (DSF, blue), and the Maybridge Ro3 NMR library (NMR, red) with respect to: (A)
polarity and hydrophobicity, expressed as calculated polar surface area versus cLogP; (B) physicochemical property coverage and diversity, expressed
as the first two principal components (pc1 and pc2) obtained from a principal component analysis (PCA) on six Lipinski-type properties.
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Maybridge Ro3 fragment library, 75 fragment hits or an initial hit
rate of 9.4% were found to bind NEIL1 with mostly weak signal
responses. Hit validation was performed with the 10 compounds
giving the strongest signal. Eight molecules (hit rate, 1.0%) were
confirmed to engage NEIL1 and subsequently tested in the
biochemical assay. Here, four compounds or 50% showed
inhibition of NEIL1-mediated Tg repair. This confirms the
findings of the DSF screens, as 40−50% of binders are inhibitors
of DNA-binding events. Questioning whether unsuitable library
chemotype composition could account for the values at the
lower end of typically observed hitrates, the screening libraries
from LCBKI for DSF and Maybridge Ro3-1000 for NMR were
compared to the exhaustive ZINC fragment library subset
(Figure 8). The observed overlap in chemical space suggests no
chemotype bias for the performed screens. In summary,
experimental hit rates are lower than expected by our initial
computational assessment. Nonetheless, a large percentage of
indentified binders are inhibitors of catalytic activity and thus are
suitable chemical starting points for an ongoing drug discovery
campaign against NEIL1.
■ SUMMARY
Here, we described a comprehensive computational druggability
assessment of human DNA glycosylases. We then assessed these
findings in an experimental setting using NEIL1 and attempted
to rationalize the difficulties in developing selective and potent
druglike inhibitors for DNA-binding proteins. Recently, DNA
glycosylases have been drawing considerable attention, with the
report of a first-in-class OGG1 inhibitor,18 followed sub-
sequently by a comprehensive study for the application of
other OGG1 inhibitors in inflammation.19Despite these results,
and to the best of our knowledge, no articles explicitly reporting
on the druggability assessment of DNA binding molecules are
available. Hajduk et al. consider proteins, which bind DNA or
RNA, and carbohydrate-binding glycosylases as representatives
of highly challenging target families.33,35 The findings reported
in the present article suggest that this conclusion is not valid for
DNA glycosylases. In contrast, when interrogated by computa-
tional measures, DNA glycosylases in general appear to be
feasable drug targets and OGG1, MUTYH, NEIL1, UNG, and
TDG, in particular, were found to be favorable drug-binding
proteins (Figures 2, 3, and 5). Our study further confirms that
DNA-binding proteins are difficult to assess with regard to
which protein state is investigated. Multiple examples were
found to be contradictory when DNA was either removed from
or retained in the same high-resolution structure of a protein.
Finally, our computational assessment suggests that catalytic
sites of DNA glycosylases are conformationally active, which is
yet unsupported by a number of high-resolution crystal
structures of the same protein (Figure 5). This observation
allows for flexible and dynamic DNA binding, enabling multiple
protein conformations that also allow small-molecule binding.
These mechanisms, which were rationalized for NEIL1 (Figures
4 and 5), allow for differences in binding of certain chemotypes
in the different stages, i.e., the presence or absence of DNA.
By employing several screening methods, we carried out an
experimental investigation of our NEIL1 druggability assess-
ment to determine if it was verifiable in vitro. Initially, a
biochemical assay using a NEIL1 substrate was applied in a HTS
to screen for small-molecule inhibitors (Figure 6). Here,
identified inhibitors failed to stabilize NEIL1 in the absence of
DNA when evaluated using DSF. In the presence of DNA,
thermal stabilization was observed for several DNA binding
proteins. Furthermore, compared to the Tm observed in these
scenarios, biochemically active compounds inhibited thermal
stabilization by DNA and thus were confirmed as binders of
NEIL1 (Figure 7). To identify binders of NEIL1, we performed
a DSF screen using 1200 rule-of-three-compliant fragments. We
identified 25 compounds (2.1%), of which 40% were confirmed
to inhibit NEIL1 enzyme activity in the biochemical assay. To
investigate whether this low hit rate was typical for DNA
glycosylases, we performed a DSF screen against OGG1. Here,
35 compounds (2.9%) were confirmed as binders, of which 46%
were inhibitors of 8-oxoG excision. Furthermore, an NMR
fragment screen was performed against NEIL1; 8 fragments
were identified to bind NEIL1, of which 50% inhibited NEIL1-
mediated Tg removal. Overall, the hit rates at the lower end of
the range typically observed for fragment screening reflect the
challenges with screening DNA glycosylases for starting points
of a prospective medicinal chemistry campaign. This stands in
contrast to the computational druggability assessments in this
article. Nevertheless, DNA glycosylases emerge as novel drug
targets,18,19,93 as they are involved in increased DNA repair
necessary in a number of diseases and general inflammation. The
present study and its findings lay the foundations as a basis for
how to address this challenging family of enzymes and to exploit
them as potential drug targets.
■ MATERIALS AND METHODS
Computational Protein Preparation. Available crystal
structures of human DNA glycosylases with the highest
resolution were imported into Maestro (Schrödinger Suite
2018-1, Schrödinger, LLC, New York, NY, 2018). NEIL1,
OGG1, MBD4, and TDG were accessible in DNA-bound and
DNA-unbound states. MPG andUNGwere only available as co-
crystals with DNA. Crystal structures of SMUG1, NTHL1, and
NEIL2 have not yet been disclosed by the scientific community.
Human MUTYH and mouse NEIL3 are available as deletion
mutants in DNA-unbound state only. MTH1 (NUDT1), a well-
characterized nucleotide-binding protein, was included as
positive control in its apo state. PTP1B was added as a negative
control. The structures were then prepared using the Protein
Preparation Wizard94−96 as implemented in Schrödinger Suite
2018-1. Briefly, protein data bank (pdb) structures were
processed by automatically assigning bond orders, adding
hydrogens, creating zero-order bonds to metals, creating
possible disulfide bridges, adding missing side chains, deleting
waters beyond 5.0 Å of hetero groups (if present), and
generating hetero states at pH 7.0. Protonation and metal
charge states were then generated for the hetero groups and
visually inspected, and the most likely states based on hydrogen-
bonding pattern and state penalty were selected. The hydrogen-
bonding networks were optimized automatically, by sampling
water orientations and optimization of hydroxyls, Asn, Gln, and
His states using ProtAssign. Subsequently, all waters with less
than four H bonds to nonwaters were removed, and finally, the
structures were submitted to a restrained minimization in the
optimized potentials for liquid simulations (OPLSs) 3 force
field,97−100 until the heavy-atom positions had converged to a
root-mean-square deviation (RMSD) of atomic positions of
0.30 Å. If present, DNA was removed in a copy of the structure
and both protein states were kept. Depending on their online
availability, protein sets comprising apo, DNA-bound, and
DNA-stripped structures were submitted to SiteMap or
exported as protein data bank (pdb) files and imported to
DogSite45 and CryptoSite44 for subsequent computational
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binding-site prediction and druggability assessment. Sequence
alignment was performed at Clustal Omega at the EMBL and
phylogenetic trees were generated using Dendroscope.101
In Silico Fragment Screening.
(1) Fragment subset selection: a subset of the ZINC Frags
Now set79 was created by applying a number of filters
implemented in a Knime workflow (Knime 3.5.2102,103).
Foremost, only fragments available from a list of 19
preferred suppliers, composed of a team of experienced
medicinal chemists, were considered. These were then
filtered using a cascade of structural filters, including
REOS,104 PAINS,105 and a set of in-house filters
(ScrapFilter). Lipinski-type descriptors (SlogP, TPSA,
AMW, NumLipinskiHBA, NumLipinskiHBD, NumRo-
tatableBonds, NumHeavyAtoms, NumRings, NumAro-
maticRings) were then calculated using the RDKit
Descriptor Calculation node. An additional descriptor
HetRatio was then calculated as the ratio of NumLi-
pinskiHBA and NumHeavyAtoms, and fragments with
HetRatio <0.2 or >0.5 were filtered out. Finally, remaining
outliers were removed by applying Gaussian Z-score
normalization on the descriptor space, filtering fragments
with descriptor values deviating more than 3 units from
themean. The entire filtering cascade reduced the original
input file of 704 041 structures as downloaded fromZINC
to 205 891 fragments.
(2) Ligand preparation: the selected fragment subset was then
prepared for docking using LigPrep (Schrodinger): the
OPLS3 force field was used for minimizations; possible
ionization states at pH 7.0 ± 2.0 were generated using
Epik,106,107 metal-binding states were added, and
tautomers were generated; specified chiralities were
retained and at most four stereoisomers were generated
per structure. This yielded 345 044 structures for docking.
(3) Docking grid generation: Glide docking grids108−110 were
generated for each target protein by focusing the grid box
on the center of the site with the highest Dscore as
determined by SiteMap.77,78
(4) Virtual screening: The virtual screening workflow as
implemented in Schrödinger Suite was used for docking,
scoring, and ranking of the top-1000 fragments against the
sites with the highest Dscore as determined by SiteMap.
The workflow comprised a cascade of docking steps with
increased accuracy (Glide HTVS→ SP→XP), where the
top-10% ranked ligands were passed on to the next step.
After Glide XP docking, the top-1000 ranked fragments
were retained for druggability assessment based on
docking scores.
Fragment Library Comparison. The 205 K fragment
subset selected from ZINC Fragments Now, DSF fragment
library, and the NMR fragment library were compared with
respect to physicochemical properties coverage. To this effect,
the structures were imported into DataWarrior 4.7.2111 and six
Lipinski-type properties were calculated: molecular weight,
cLogP, H-bond acceptor count, H-bond donor count, polar
surface area, and rotatable bond count. Principal component
analysis (PCA) was then applied to the descriptor matrix to be
able to visualize this six-dimensional space and compare the
libraries in two dimensions.
Recombinant Proteins. APE1 was expressed from
pET14b, and OGG1 from pNIC28a with N-terminal histidine
tags. TDG, NEIL1, and NEIL2 were expressed from pET-28a.
NEIL1 and NEIL2 contained C-terminal histidine tags, whereas
TDG contained an N-terminal histidine tag. The pET-28a-
NEIL1Δ56 expression construct was generated using FastClon-
ing.112 APE1 and OGG1 were expressed and purified as
described here.19 Full-length NEIL1 and NEIL2, NEIL1Δ56,
and TDG were purified by the Protein Science Facility at
Karolinska Institutet. Escherichia coli endonuclease VIII were
purchased from New England Biolabs (M0299).
HTS Compound Library. Screening for inhibitors of NEIL1
was performed at the Laboratories of Chemical Biology
Karolinska Institutet (LCBKI), part of Chemical Biology
Consortium Sweden, using a compound concentration of 10
μm in 384-well microtiter plates (black OptiPlates, PerkinElm-
er). Rule-of-five-compliant, quality-controlled compounds
originating from Enamine were screened, along with an
LCBKI in-house compound library (donated by Biovitrum
AB). All assay plates contained test compounds in columns 1−
22, whereas negative and positive controls in columns 23 and 24
were used for normalization. In this layout, the negative controls
represent the uninhibited enzyme, corresponding to empty wells
or wells with the equivalent amount of DMSO as the compound
containing wells, whereas the positive controls represent the
completely inhibited enzyme, owing to the presence of 100 μM
of the previously discovered NEIL1 inhibitor CGP-74514A48
HTS-Compatible DNAGlycosylase Activity Assays.The
NEIL1 activity assay was performed at room temperature in
black 384-well plates (blackOptiPlates, PerkinElmer) using final
concentrations of 25 mM Tris-HCl pH 8.0, 20 mM KCl, 1 mM
EDTA, 0.5 mM DTT, 0.1% bovine serum albumin, 0.0025%
Tween-20, 10 nMNEIL1 enzyme, and 20 nMTg/A substrate in
a final volume of 25 μL. The Tg/A substrate was a duplex
oligonucleotide where 5-(dT-FAM)CTG CCA YCA CTG
CGTCGACCTG-3 was annealed to a 25% surplus of 5-CAG
GTC GAC GCA GTG CTG GCA G(dT-DABCYL)-3. “Y”
signifies thymidine glycol, and “dT-FAM” and “dT-DABCYL”
signify fluorescein and dabcyl, respectively, both coupled to dT
(TriLink BioTechnologies). Briefly, compounds dissolved in
DMSO were dispensed using an Echo 550 (Labcyte), followed
by transfer of enzyme and substrate solutions by a MultiDrop
(PerkinElmer), followed by centrifugation at 1000 g to remove
bubbles. The reactions were read after 20 min in an Envision
plate reader using a 485 nm filter with a bandwidth of 14 nm for
excitation and a 535 nm filter with a bandwidth of 25 nm for
emission. OGG1 activity was measured as described here.19
DNA Intercalation Counterscreen. DNA intercalation
was measured by incubating 20 nM unlabeled, undamaged
oligonucleotides in NEIL1 reaction buffer (excluding bovine
serum albumin) in the presence of 100 nM Thiazole Orange
(Sigma-Aldrich 390 062) as described in ref 113.
DSF Fragment Library. The laboratory for chemical
biology at Karolinska Institutet (LCBKI)-based fragment library
consists of 1200 rule-of-three-compliant substances, which have
been filtered for undesirable functionalities and PAINS. Along
with a versatile set of chemotypes, the library also contains a
population of small-molecule nucleotide analogues for specifi-
cally targeting DNA-, nucleotide-, and nucleoside-binding
proteins. All substances were obtained commercially from
different vendors (Enamine, Activate Scientific, Combi-Blocks,
Sigma-Aldrich, Fisher Scientific, AK Scientific, abcr Chemie,
Fluorochem, Spirochem, KeyOrganics, 1Click Chemistry,
VWR, TCI, ChemBridge, Carbosynth) or from the NCI
Developmental Therapeutics Program and are stored at 4 °C
as 50 mM DMSO stock solutions.
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DSF Fragment Screen.White BioRad 384-well plates with
duplicates of each compound, DMSO, and positive control were
prepared. Next, 9.8 μL of protein buffer, containing 25mMTris-
acetate pH 7.5, 150 mM NaCl, 10% glycerol, 1 mM DTT, 5X
SYPRO Orange, and 4 μM NEIL1, lacking 56 amino acids
dispensable for activity at the disordered C-Terminus, was
added to each well, yielding a final protein concentration of 3.92
μM and a final compound concentration of 1 mM. Similarly, 4
μMOGG1 was screened in 25 mM Tris-acetate pH 7.5, 50 mM
CaCl2, 10% glycerol, 1 mM DTT, 5X SYPRO Orange. The
plates were sealed with BioRad MicroSeal ‘B’ and subjected to a
temperature gradient from 20 to 95 °C in a Roche Light Cycler
480 II. The resulting fluorescence at 465−580 nm with an
excitation wavelength of 465 nm was measured. Visual quality
control of each graph was performed, and the resulting data were
processed and imported to a GraphPad Prism template provided
by Niesen et al.90 For optimization and DNA experiments not
concerning the fragment screens, black BioRad Hard-Shell PCR
96-well thin-wall plates were used in a BioRad C1000 Touch
Thermal Cycler with 510 nm excitation wavelength and
measurement at 465 nm. NEIL2, APE1, and TDG were
prepared in a protein buffer containing 4 μm protein, 25 mM
Tris-acetate pH 7.5, 150 mM NaCl, 10% glycerol, 1 mM DTT,
and 5X SYPRO Orange.
DNA Oligo Preparation and DSF Use. DNA oligos of
different sequences were obtained from IDT and TriLink: 50
base pairs: (5-TAC GCT AGT ATG CGT TCT TCC TTC
CAG GGG TAT GTG GCT GCG TGG TCA AA-3 and 5-
TTT GAC CAC GCA GCC ACA TAC CCC TGG AAG GAA
GAA CGC ATA CTA GCG TA-3), 100 base pairs: (5-CCT
GAC GCT AGT GCA AAA CAC CCA AGC GAC CCT GAC
AGT GCG AAT TGG CGA GCC TTA AGC TCT TTC GTT
TGC TGA CGA GCG TTG CTG CGA GAC TGG CTT G-3
and 5-CAAGCCAGTCTCGCAGCAACGCTCGTCAGC
AAA CGA AAG AGC TTA AGG CTC GCC AAT TCG CAC
TGTCAGGGTCGC TTGGGTGTT TTGCAC TAGCGT
CAG G-3), APE abasic-site analogue, 29 base pairs: (5-TGT
ATCGATACCXTCAACCTCGAGGAATT and AATTCC
TCG AGG TTG AGG TAT CGA TAC A-3, where X signifies
tetrahydrofuran), 100 base pairs: (5-CTT CAA CCT CGA
GGA ATG TAT CGA TAC CTT CAA CCT CGA GGA ATG
TAT CGA TAC CTT CAA CCT CGA GGA ATG TAT CGA
TAC CTT CAA CCT CGA GGA ATT-3 and 5-AAT TCC
TCG AGG TTG AAG GTA TCG ATA CAT TCC TCG AGG
TTG AAG GTA TCG ATA CAT TCC TCG AGG TTG AAG
GTATCGATACATTCCTCGAGGTTGAAG-3), thymine
glycole control, 29 base pairs: (5-TGT ATC GAT ACC TTC
AAC CTC GAG GAA TT and 5-AAT TCC TCG AGG ATG
ACGGTA TCG ATA CA-3), 8-oxo G, 29 base pairs: (5-TGT
ATC GAT ACC YTC AAC CTC GAG GAA TT and 5-AAT
TCC TCG AGG TTG ACG GTA TCG ATA CA-3, where Y
signifies 8-oxoG), thymine glycol, 29 base pairs: (5-TGT ATC
GATACCZTCAACCTCGAGGAATT-3 and 5-AATTCC
TCGAGGTTGAAGGTATCGATACA-3, where Z signifies
thymine glycol); 200 μM DNA oligo stock solutions were
prepared in a buffer system containing 25 mM Tris-acetate pH
7.5, 150 mMNaCl, and 10% glycerol and stored at−20 °C. The
required amounts of the complementary strands were combined
in a 1:1 ratio and heated to 90 °C for 1 min. Storing at room
temperature for 1 h and then cooling on ice allows for DNA
double-strand generation in a 200 μM stock solution. After
optimization of DNA concentration, 8 μM DNA was used for a
standard experiment.
Statistical Analysis DSF Fragment Screen. Statistical
analysis of all graphs was performed with the DSF template
provided by Niesen et al.90 The nonlinear fit performed by
GraphPad Prism considers half the difference between a
pretransitional minimum and a post-transitional maximum to
be the melting temperature of the protein.
NMR Fragment Screen. NEIL1 in 20 mM HEPES, 300
mM NaCl, 10% glycerol, 2 mM TCEP, pH 7.5 was dialyzed
against 1× PBS, pH 7.4 overnight, and added to fragment
mixtures containing 10 compounds, each leading to a final
concentration of 10 μm NEIL1 and 100 μM of compound. The
fragment mixtures were prepared from 100mMDMSO-d6 stock
solutions, diluted in 1× PBS pH 7.4 containing 10%D2O and 50
μm trimethylsilylpropanoic acid (TMSP-d4) as a chemical shift
reference. A Bruker SamplePro liquid handling system with
cooling was used to transfer samples to 3 mm NMR tubes. A
total of 800 compounds, selected from the Maybridge Ro3 1000
fragment library (www.maybridge.com), were used in the
screening. Both T2-filtered spectra
114 and saturation transfer
difference (STD) spectra115 were recorded on all samples. A
Carr−Purcell−Meiboom−Gill (CPMG) spin-lock of 200 ms
was used in the T2-filtered experiment, and in the STD
experiment, on- and off-resonance saturations at 0.85 and −40
ppm were achieved with 40 and 50 ms Gaussian-shaped pulses,
respectively. A total of 64 scans were recorded for both
experiments. Reference spectra on fragment mixtures without
NEIL1 were recorded separately. The NMR screen was
performed within the NMR for Life (www.nmrforlife.se)
initiative at the Swedish NMR Centre, Umeå, Sweden. All
spectra were recorded on a Bruker 600 MHz Avance III HD
spectrometer equipped with a 5 mm TCI cryoprobe and a
SampleJet sample changer with cooling option. Spectral
processing and analysis was performed in Topspin 4.0.1
(www.bruker.com). Hit validation was performed by repeating
the experiments described above on individual compounds
instead of mixtures.
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